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INTRODUCTION 
 Cardiovascular autonomic neuropathy (CAN), a common form of 
autonomic dysfunction found in patients with diabetes mellitus, causes 
abnormalities in heart rate control, as well as defects in central and peripheral 
vascular dynamics. Individuals with parasympathetic dysfunction have a 
high resting heart rate most likely because of vagal neuropathy that results in 
unopposed increased sympathetic outflow. Persons with a combined 
parasympathetic/sympathetic dysfunction have slower heart rates. With 
advanced nerve dysfunction, heart rate is fixed. Thus, it is apparent that the 
determination of heart rate itself is not a reliable diagnostic sign of CAN. 
Reduction in variability of heart rate is the earliest indicator of CAN. 
Cardiovascular autonomic neuropathy occurs in ~17% of patients with type 
1 diabetes and 22% of those with type 2. An additional 9% of type 1 patients 
and 12% of type 2 patients have borderline dysfunction. In a review of 
several epidemiological studies among individuals with diabetes, the 5-year 
mortality rate is five times higher for individuals with cardiovascular 
autonomic neuropathy than for individuals without cardiovascular autonomic 
involvement. The autonomic nervous system, which includes the 
parasympathetic and sympathetic systems, plays an important role in the 
regulation of myocardial function, heart rate, and myocardial blood flow. The 
sympathetic system innervates the myocardium via sympathetic nerve fibers 
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that traverse the subendocardium along the path of the coronary vessels, from 
the base to the apex of the heart. Extended increased stimulation of cardiac 
adrenergic receptors results in desensitization and downregulation of the 
receptors, as well as increased receptor degradation and decreased receptor 
synthesis. In diabetes, CAN is ultimately the result of complex interactions 
among degree of glycemic control, disease duration, age-related neuronal 
attrition, and systolic and diastolic blood pressure.  
Hyperglycemia plays the key role in the activation of various 
biochemical pathways related to the metabolic and/or redox state of the cell, 
which, in concert with impaired nerve perfusion, contribute to the 
development and progression of diabetic neuropathies. Experimental data 
implicate a number of pathogenic pathways that may impact autonomic 
neuronal function in diabetes including: formation of advanced glycation end 
products, increased oxidative/nitrosative stress with increased free radical 
production, activation of the polyol and protein kinase C pathways, 
activation of poly ADP ribosylation, and activation of genes involved in 
neuronal damage . 
Clinical Manifestations of Cardiovascular Autonomic Dysfunction 
Exercise intolerance  
In diabetic individuals with CAN, exercise tolerance is limited as a 
result of impaired parasympathetic/sympathetic responses that would 
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normally enhance cardiac output and result in directing peripheral blood flow 
to skeletal muscle. 
Intra-operative cardiovascular liability: 
There is a 2- to 3-fold increase in cardiovascular morbidity and 
mortality intra-operatively for patients with diabetes. Studies have 
demonstrated that the induction of anesthesia causes a greater degree of 
decline in heart rate and blood pressure in diabetic patients compared with 
non-diabetic individuals  and that hemodynamic stability, in the intra-
operative period, depends on the severity of autonomic dysfunction .  
Orthostatic hypotension OH is characterized by a defect in this reflex 
arc, resulting in signs and symptoms such as weakness, faintness, dizziness, 
visual impairment, and syncope. Although the absolute fall in blood pressure 
is arbitrary, OH is usually defined as a fall in blood pressure [i.e. >20–30 mm 
Hg for systolic or >10 mm Hg for diastolic in response to postural change, 
from supine to standing.  
Painless myocardial ischemia  
Inability to detect ischemic pain can impair the recognition of 
myocardial ischemia or MI. The mechanisms of painless myocardial 
ischemia are, however, complex and not fully understood. Altered pain 
thresholds, sub threshold ischemia not sufficient to induce pain, and 
dysfunction of the afferent cardiac autonomic nerve fibers have all been 
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suggested as possible mechanisms .A recent investigation that used positron 
emission tomography to measure regional cerebral blood flow as an index of 
regional neuronal activation has shown that impaired afferent signaling 
resulting from autonomic dysfunction is associated with failed signal 
transmission from the thalamus to the frontal cortex ..  
Increased risk of mortality  
Impaired autonomic control of heart rate is linked to increased risk of 
mortality. Reduced parasympathetic function or increased sympathetic 
activity may provide the propensity for lethal arrhythmias.   
Measurement of Cardiovascular Autonomic Function 
   In the early 1970s, Ewing et al proposed five simple noninvasive 
cardiovascular reflex tests (Valsalva maneuver, heart rate response to deep 
breathing, heart rate response to standing up, blood pressure response to 
standing up, and blood pressure response to sustained handgrip) that have 
been applied successful. Today, sensitive and early assessment of 
cardiovascular autonomic neuropathy is possible by means of noninvasive 
autonomic function tests, including power spectral analysis of a series of 
successive R-R intervals (frequency domain analyses). This can be 
performed on short R-R sequences (e.g.,7 minute) or on 24-hour 
electrocardiogram recordings. The heart rate power spectrum is typically 
divided into two frequency bands: low (0.04 to 0.15 Hz) and high (0.15 to 
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0.4 Hz). The high-frequency region is generally considered a marker of vagal 
activity, whereas the low-frequency component is influenced by both 
sympathetic and vagal activity. 
The association of mortality and cardiovascular autonomic 
dysfunction indicates that individuals with abnormal autonomic function 
tests are candidates for close surveillance. Thus it has been recommended 
that a baseline determination of cardiovascular autonomic function be 
performed upon diagnosis in type 2 diabetes and within 5 years of diagnosis 
for those with type 1 diabetes, followed by a yearly repeat test. In addition, 
the presence of autonomic dysfunction should alert the health care 
professional to search for associated risk factors of cardiovascular disease 
and implementation of an intense program to reduce these factors and 
thereby reduce the risk of mortality.  
Treatment Interventions to Ameliorate Cardiovascular Autonomic 
Dysfunction via Pharmacological Agents  
Interventions to ameliorate reduced HRV are being evaluated in 
clinical trials based on theories of the pathogenesis of diabetic neuropathy. 
Development of diabetic neuropathy is the result of a multifactorial process 
including metabolic insult to nerve fibers, neurovascular insufficiency, 
increased oxidative stress, reduction in neurotrophic growth factors, 
deficiency of essential fatty acids, formation of advanced glycosylation end 
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products, and autoimmune damage .Various pharmacological agents that are 
directed at components of the pathogenic process are described below. 
Clinical assessment of cardiac autonomic nervous system 
 
Clinical 
observation 
Method of measurement Normal 
value 
I.parasympathete
ic nervous system 
 
*Heart rate 
response to 
valsalva 
Patients’ blows into a mouth piece maintaining a 
pressure of 40 mmHG for 15 seconds. The 
valsalva ratio is the ratio of the longest R-R 
interval on the ECG immediately after release to 
the shortest R-R interval during the maneuver. 
Ratio > 1.21
*Heart rate 
response to 
standing  
Heart rate is measured as the patient changes 
from supine to standing position (increase 
maximal around 15 th beat after standing and 
slowing maximal around 30 th beat).the 
response to standing is expressed as the 30:15 
ratio and is the ratio of the longest R-R interval( 
around 30 th beat ) to the shortest R-R interval 
(around 15 th beat). 
Ratio >1.04 
*Heart rate 
response to deep 
breathing 
Patients take six deep breaths in 1 minute.the 
maximum and minimum heart rates during each 
cycle are measured and the mean of the 
differences (maximum heart rate-minimum heart 
rate) during three successive breathing cycles is 
taken as the maximum – minimum heart rate. 
Mean 
difference 
>15 BPM 
II. sympathetic 
system 
  
*Blood pressure 
response to 
standing 
The patients changes from the supine to standing 
position and the standing systolic blood pressure 
is subtracted from the supine systolic blood 
pressure 
Difference < 
10 mmHG 
*Blood pressure 
response to 
sustained handgrip 
The patients maintain a hand grip of 30% of 
maximum squeeze for up to 5 minutes. The 
blood pressure is measured every minute and the 
initial diastolic blood pressure is subtracted from 
the diastolic blood pressure just prior to release 
Difference 
>16 mmHG 
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Glycemic control   
The results of the Diabetes Control and Complications Trial showed 
that intensive treatment prevented the development of abnormal RR variation 
and slowed the deterioration of autonomic dysfunction over time.  
Antioxidants   
During chronic hyperglycemia, the metabolism of glucose also results 
in the generation of free radicals. -Lipoic acid, an antioxidant that reduces 
free radical formation, appears to slow progression of CAN. For persons with 
type 2 diabetes, the improvement in CAN was seen after 4 months of 
treatment with an oral dosage of 800 mg/d.  
Angiotensin converting enzyme (ACE) inhibitors  
In human diabetic neuropathy, impaired nerve blood flow has been 
demonstrated Given that vascular dysfunction may be part of the 
pathogenesis of diabetic neuropathy, ameliorating this abnormality may 
positively benefit nerve function. ACE inhibitors promote vasodilatation by 
preventing the generation of angiotensin II and by preventing the breakdown 
of bradykinin. Angiotensin II, in addition to its role as a vasoconstrictor, 
stimulates aldosterone release and promotes sympathetic outflow, thus ACE 
inhibitors may provide additional benefits as a result of the inhibition of 
angiotensin II.  
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Aldosterone blockers  
Aldosterone has been shown to affect the autonomic nervous system 
with sympathetic activation and parasympathetic inhibition and impair the 
baroreflex response Other dysfunctions associated with aldosterone include 
the blockage of myocardial uptake of nor epinephrine in animal models and 
decreased arterial and venous compliance, leading to vascular organ damage 
.Spironolactone, an aldosterone-receptor blocker, has been used to reduce the 
morbidity and mortality 
Calcium-channel blockers  
  Although the mechanism by which verapamil influences HRV is not 
clear, it may be due to specific properties of the drug that have a suppressive 
effect on sympathetic outflow of catecholamines. Calcium-channel blockers 
may not, however, have a beneficial effect on HRV in persons with diabetes. 
For example, verapamil had no effect on HRV in diabetic subjects post-MI, 
whereas long-acting calcium antagonists enhanced, rather than reduced, 
sympathetic activity in patients with type 2 diabetes  
ß-Blockers  
The use of ß-blockers in diabetic patients has been questioned because 
these agents may mask signs and symptoms of hypoglycemia and interfere 
with insulin release.  In the ß-blocker Heart Attack Trial, propranolol 
improved recovery of parasympathetic tone and decreased morning 
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sympathetic predominance for post-MI patients. The addition of metoprolol 
to ramipril-treated type 1 diabetic patients with abnormal albuminuria was 
also shown to improve autonomic dysfunction  
Metformin  
Free fatty acids (FFAs) interfere with glucose metabolism .Under 
normal circumstances, FFAs are the main fuel source for the heart .Recently, 
it has been shown that the combination of TNF-  and hyperglycemia 
stimulated lipolysis with a consequential increase in FFAs and induced 
insulin resistance .Decreased activation of the parasympathetic nervous 
system increases lipolysis, thus resulting in an increased concentration of 
FFAs in the plasma .An increase in FFAs has been shown to affect the 
cardiovascular system through activation of the sympathetic nervous system 
in healthy subjects ,as well as in individuals with type 2 diabetes .Recently, it 
was demonstrated that overweight type 2 diabetic patients had metformin-
related decreases in FFAs and insulin resistance that were associated with 
improved sympathovagal balance . 
Treatment Interventions to Ameliorate Cardiovascular Autonomic 
Dysfunction via Nonpharmacological Agents  
It is well known that exercise plays an important role in the treatment 
of diabetes. The role of exercise in the improvement of cardiovascular 
autonomic function is not as clear. Endurance training was also shown to 
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improve vagal activity in nondiabetic patients who had a MI (and in insulin-
requiring diabetic individuals with early CAN other studies showed no 
benefit or only minimal benefit for healthy men and individuals with type 2 
diabetes. 
Investigational Medications for Potential Use for Cardiovascular 
Autonomic Dysfunction  
 Aldose reductase inhibitors  
Chronic hyperglycemia causes activation of the polyol pathway with 
the accumulation of sorbitol and fructose, resulting in various metabolic 
imbalances that lead to neuronal dysfunction .In the early 1980s, aldose 
reductase inhibitors (ARIs), which reduce activity in the polyol pathway, 
generated hope with regard to the potential treatment of diabetic neuropathy. 
Due to lack of safety and/or efficacy, however, several ARIs have been 
withdrawn from the market and currently no ARIs are available for use in the 
U.S. One ARI (i.e. epalrestat) has been marketed in Japan since 1995. 
Whereas two studies have shown improved measures of CAN with epalrestat 
administration another study showed no effect of epalrestat on cardiac 
sympathetic dysfunction. Newer agents such as fidarestat and AS-3201 are 
being investigated in ongoing clinical trials assessing peripheral neuropathy.  
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AIM OF THE STUDY 
This study aimed on Pre-operative evaluation for diabetic autonomic 
neuropathy using CANS 504 (cardiac autonomic neuropathy system 
analyzer) and their behavior during regional anesthesia. 
 
Inclusion criteria: 
Case: 
• Age: 40- 60 years. 
• Sex: both male and female. 
• Diabetes mellitus > 3 years 
• PS II & III 
 
Control:  
• Age: 40- 60 years. 
• Sex: both male and female. 
• Not a known diabetes mellitus  
• PS I 
 
Exclusion criteria: 
• age < 40 & >60 years.  
• PS IV 
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Equipments required: 
• CANS 504 – cardiac autonomic neuropathy system analyzer. 
• ECG monitor 
• Sphygmomanometer. 
• pulse oxymeter. 
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ANATOMY AND PHYSIOLOGY OF ANS 
Langley (1852-1925) coined the term autonomic nervous system.ANS 
innervation is divided into sympathetic nervous system and parasympathetic 
nervous system divisions. The sympathetic division has thoracolumbar 
“outflow”, meaning that the neurons begin at the thoracic and lumbar (T1-
L2) portions of the spinal cord. The parasympathetic division has 
craniosacral “outflow”, meaning that the neurons begin at the cranial nerves 
(CN 3, CN7, CN 9, CN10) and sacral (S2-S4) spinal cord. 
The ANS is unique in that it requires a sequential two-neuron efferent 
pathway; the preganglionic neuron must first synapse onto a postganglionic 
neuron before innervating the target organ. The preganglionic, or first, 
neuron will begin at the “outflow” and will synapse at the postganglionic, or 
second, neuron’s cell body. The post ganglionic neuron will then synapse at 
the target organ.  
Anatomy 
Sympathetic division 
The sympathetic division (thoracolumbar outflow) consists of cell 
bodies in the lateral horn of spinal cord (intermediolateral cell columns) of 
the spinal cord from T1 to L2. These cell bodies are GVE neurons (general 
visceral efferent), and are the preganglionic neurons. There are several 
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locations upon which preganglionic neurons can synapse for their 
postganglionic neurons: 
• Paravertebral ganglia of the sympathetic chain (these run on either 
side of the vertebral bodies) 
• Prevertebral ganglia (celiac ganglia, superior mesenteric ganglia, 
inferior mesenteric ganglia) 
• Chromaffin cells of adrenal medulla (this is the one exception to the 
two-neuron pathway rule: synapse is direct onto cell bodies) 
These ganglia provide the postganglionic neurons from which innervation of 
target organs follows. Examples of splanchnic (visceral) nerves are: 
• Cervical cardiac nerves & thoracic visceral nerves which synapse in 
the sympathetic chain 
• Thoracic splanchnic nerves (greater, lesser, least) which synapse in the 
prevertebral ganglion 
• Lumbar splanchnic nerves which synapse in the prevertebral ganglion 
• Sacral splanchnic nerves which synapse in the inferior hypogastric 
plexus 
These all contain afferent (sensory) nerves as well, also known as GVA 
neurons (general visceral afferent). 
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Parasympathetic division 
The parasympathetic division (craniosacral outflow) consists of cell 
bodies from one of two locations: brainstem (Cranial Nerves 3, 7, 9, 10) or 
sacral spinal cord (S2, S3, S4). These are the preganglionic neurons, which 
synapse with postganglionic neurons in these locations: 
• Parasympathetic ganglia of the head (Ciliary (CN3), Submandibular 
(CN7), Pterygopalatine (CN7), Otic (CN9)) 
• In or near wall of organ innervated (Vagus (CN10), Sacral nerves (S2, 
S3, S4)) 
These ganglia provide the postganglionic neurons from which innervations 
of target organs follows. Examples are: 
• The preganglionic parasympathetic splanchnic (visceral) nerves 
• Vagus nerve, which wanders through the thorax and abdominal 
regions innervating, among other organs, the heart, lungs, liver and 
stomach 
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Sensory neurons 
The sensory arm is made of “primary visceral sensory neurons” found 
in the peripheral nervous system (PNS), in “cranial sensory ganglia”: the 
geniculate, petrosal and nodose ganglia, appended respectively to cranial 
nerves VII, IX and X. These sensory neurons monitor the levels of carbon 
dioxide, oxygen and sugar in the blood, arterial pressure and the chemical 
composition of the stomach and gut content. (They also convey the sense of 
taste, a conscious perception). Blood oxygen and carbon dioxide are in fact 
directly sensed by the carotid body, a small collection of chemosensors at the 
bifurcation of the carotid artery, innervated by the petrosal (IXth) ganglion. 
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Primary sensory neurons project (synapse) onto “second order” or relay 
visceral sensory neurons located in the medulla oblongata, forming the 
nucleus of the solitary tract (nTS), that integrates all visceral information. 
The nTS also receives input from a nearby chemosensory center, the area 
postrema, that detects toxins in the blood and the cerebrospinal fluid and is 
essential for chemically induced vomiting or conditional taste aversion (the 
memory that ensures that an animal which has been poisoned by a food 
never touches it again). All these visceral sensory information’s constantly 
and unconsciously modulate the activity of the motor neurons of the ANS 
Motor neurons 
Motor neurons of the ANS are also located in ganglia of the PNS, 
called “autonomic ganglia”. They belong to three categories with different 
effects on their target organs (see below “Function”): sympathetic, 
parasympathetic and enteric. 
Sympathetic ganglia are located in two sympathetic chains close to the 
spinal cord: the prevertebral and pre-aortic chains. Parasympathetic ganglia, 
in contrast, are located in close proximity to the target organ: 
the submandibular ganglion close to salivary glands, paracardiac ganglia 
close to the heart etc... Enteric ganglia, which as their name implies 
innervate the digestive tube, are located inside its walls and collectively 
contain as many neurons as the entire spinal cord, including local sensory 
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neurons, motor neurons and interneurons. It is the only truly autonomous 
part of the ANS and the digestive tube can function surprisingly well even in 
isolation. For that reason the enteric nervous system has been called “the 
second brain”. 
The activity of autonomic ganglionic neurons is modulated by 
“preganglionic neurons” (also called improperly but classically "visceral 
motoneurons") located in the central nervous system. Preganglionic 
sympathetic neurons are in the spinal cord, at thoraco-lumbar levels. 
Preganglionic parasympathetic neurons are in the medulla oblongata 
(forming visceral motor nuclei: the dorsal motor nucleus of the vagus 
nerve (dmnX), the nucleus ambiguus, and salivatory nuclei) and in the sacral 
spinal cord. Enteric neurons are also modulated by input from the CNS, from 
preganglionic neurons located, like parasympathetic ones, in the medulla 
oblongata (in the dmnX). 
The feedback from the sensory to the motor arm of visceral reflex 
pathways is provided by direct or indirect connections between the nucleus 
of the solitary tract and visceral motoneurons. 
Function 
Sympathetic and parasympathetic divisions typically function in 
opposition to each other. But this opposition is better termed complementary 
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in nature rather than antagonistic.  Consider sympathetic as "fight or flight" 
and parasympathetic as "rest and digest". 
Sympathetic nervous system 
Promotes a "fight or flight" response, corresponds with arousal and 
energy generation, and inhibits digestion. 
• Diverts blood flow away from the gastro-intestinal (GI) tract(α1) 
and skin(α1 α2) via vasoconstriction. 
• Blood flow to skeletal muscles (α1,β2) and the lungs(α1,β2) is 
enhanced (by as much as 1200% in the case of skeletal muscles). 
• Dilates bronchioles of the lung (β2), which allows for greater alveolar 
oxygen exchange. 
• Increases heart rate and the contractility of cardiac cells (β1,β2) 
(myocytes), thereby providing a mechanism for the enhanced blood 
flow to skeletal muscles. 
• Dilates pupils (α1) and relaxes the ciliary muscle to the lens (β2), 
allowing more light to enter the eye and far vision.\ 
• Provides vasodilation for the coronary vessels of the heart (β2). 
• Constricts all the intestinal sphincters (α1) and the urinary sphincter 
(α1). 
• Inhibits peristalsis (α1, α2, β2). 
• Stimulates orgasm (α1). 
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• Glucose released into blood from liver(α1,β2) ,breakdown of glycogen 
to glucose in skeletal muscle (β2) 
• Fat breakdown and release of fatty acids(β3) 
Parasympathetic nervous system 
Promotes a "rest and digest" response, promotes calming of the nerves 
return to regular function, and enhances digestion (m receptors). 
• Dilates blood vessels leading to the GI tract, increasing blood flow. 
This is important following the consumption of food, due to the 
greater metabolic demands placed on the body by the gut. 
• The parasympathetic nervous system can also constrict the bronchiolar 
diameter when the need for oxygen has diminished. 
• Dedicated cardiac branches of the Vagus and thoracic Spinal 
Accessory nerves impart Parasympathetic control of the Heart or 
Myocardium.  
• During accommodation, the parasympathetic nervous system causes 
constriction of the pupil and contraction of the ciliary muscle to the 
lens, allowing for closer vision. 
• The parasympathetic nervous system stimulates salivary gland 
secretion, and accelerates peristalsis, so, in keeping with the rest and 
digest functions, appropriate PNS activity mediates digestion of food 
and indirectly, the absorption of nutrients. 
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• Is also involved in erection of genitals, via the pelvic splanchnic 
nerves 2–4. 
• Stimulates sexual arousal. 
Neurotransmitters and pharmacology 
At the effector organs, sympathetic ganglionic neurons release 
noradrenalin (norepinephrine), along with other cotransmitters such as ATP, 
to act on adrenergic receptors, with the exception of the sweat glands and the 
adrenal medulla: 
• Acetylcholine is the preganglionic neurotransmitter for both divisions of 
the ANS, as well as the postganglionic neurotransmitter of 
parasympathetic neurons. Nerves that release acetylcholine are said to be 
cholinergic. In the parasympathetic system, ganglionic neurons use 
acetylcholine as a neurotransmitter, to stimulate muscarinic receptors. 
• At the adrenal cortex, there is no postsynaptic neuron. Instead the 
presynaptic neuron releases acetylcholine to act on nicotinic receptors. 
• Stimulation of the adrenal medulla releases adrenaline (epinephrine) into 
the bloodstream which will act on adrenoceptors, producing a 
widespread increase in sympathetic activity  
 
 
 
 
 
28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
29 
 
PHARMACOLOGY 
Dopamine 
Dopamine is a neurotransmitter activating dopamine receptors. The 
hypothalamus also releases it as a neurohormone, with its main function the 
inhibition of prolactin release from the anterior pituitary lobe. Dopamine is 
available as an intravenous medication acting on the sympathetic nervous 
system, producing effects such as increased heart rate and blood pressure. 
Increased dopamine can improve the symptoms of people with Parkinson's 
disease and other related disorders; however, dopamine itself cannot cross 
the blood-brain barrier, so injecting or ingesting it does not get it to the brain. 
Instead, a synthetic L-DOPA, which is a precursor to dopamine that does 
cross the blood-brain barrier, can  be used 
History:  
          Dopamine was first synthesized in 1910 by George Barger and James 
Ewens at Wellcome Laboratories in London, England. Dopamine's function 
as a neurotransmitter was first recognized in 1958 by Arvid Carlsson and 
Nils-Åke Hillarp at the Laboratory for Chemical Pharmacology of the 
National Heart Institute of Sweden.   
Synthesis 
Dopamine is a member of the catecholamine family, and is a precursor 
to epinephrine (or adrenaline) and norepinephrine (noradrenaline).  
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Dopamine is synthesized by the decarboxylation of DOPA by aromatic-L-
amino-acid decarboxylase. 
Inactivation and degradation 
Two major degradation pathways for dopamine exist. In most areas of 
the brain, including the striatum and basal ganglia, dopamine is inactivated 
by reuptake via the dopamine transporter (DAT1), then enzymatic 
breakdown by monoamine oxidase (MAOA and MAOB) into 3,4-
dihydroxyphenylacetic acid. In the prefrontal cortex, however, there are very 
few dopamine transporter proteins, and dopamine is instead inactivated by 
reuptake via the norepinephrine transporter (NET), presumably on 
neighboring norepinephrine neurons, then enzymatic breakdown 
by catechol-O-methyl transferase (COMT) into 3-methoxytyramine.  
Therapeutic Uses 
Dopamine acts upon receptors present on immune cells, with all 
subtypes of dopamine receptors found on  Levodopa is a dopamine precursor 
used in various forms to treat Parkinson's disease and dopa-
responsive dystonia. 
Peripheral effects 
Dopamine also has effects when administered through an IV line 
outside the central nervous system. The brand name of this preparation is 
known as Intropin. The effects in this form are dose dependent. 
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• Dosages from 2 to 5 μg/kg/min are considered the "renal dose." At this 
low dosage, dopamine binds D1 receptors, dilating blood vessels, 
increasing blood flow to renal, mesenteric, and coronary arteries; and 
increasing overall renal perfusion. Dopamine therefore has a diuretic 
effect, potentially increasing urine output from 5 ml/kg/hr to 10 
ml/kg/hr 
• Intermediate dosages from 5 to 10 μg/kg/min additionally have a 
positive inotropic and chronotropic effect through increased β1 
receptor  activation. It is used in patients with shock or heart failure to 
increase cardiac output and blood pressure. Dopamine begins to affect 
the heart at the lower doses, from about 3 μg/kg/min IV. 
• High doses from 10 to 20 μg/kg/min is the "presser" dose. This dose 
causes vasoconstriction, increases systemic vascular resistance, and 
increases blood pressure through α1receptor activation; but can cause 
the vessels in the kidneys to constrict to the point where they will 
become non-functional 
Renal effects 
Dopamine induces natriuresis (sodium loss) in the kidneys. 
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Ephedrine 
Ephedrine is a sympathomimetic amine commonly used as a 
stimulant, appetite suppressant, concentration aid, decongestant, and to 
treat hypotension associated with anesthesia. Nagayoshi Nagai, a Japanese 
chemist, was the first person to isolate ephedrine from Ephedra 
distachya (syn. Ephedra vulgaris) in 1885. 
Mechanism of action 
Ephedrine is a sympathomimetic amine. The principal mechanism of 
its action relies on its indirect stimulation of the adrenergic receptor system, 
which is part of the sympathetic nervous system (SNS), by increasing the 
activity of noradrenaline at the post-synaptic α- and β-receptors.  
Indications 
 Both ephedrine and pseudoephedrine act as a bronchodilator, but 
pseudoephedrine has considerably less effect. Both also increase blood 
pressure, with again pseudoephedrine being considerably less effective  
popular supplement taken by body builders to cut down body fat before a 
competition. For many years, the US Coast Guard recommended ephedrine 
together with an equal 25 mg dose of promethazine to its sailors to 
combat seasickness.  
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Adverse effects 
Adverse drug reactions (ADRs) are more common with systemic 
administration (e.g. injection or oral administration) compared to topical 
administration (e.g. nasal instillations). ADRs associated with ephedrine 
therapy include: Cardiovascular: tachycardia, cardiac arrhythmias, angina 
pectoris, vasoconstriction with hypertension Dermatological: flushing, 
sweating, acne vulgaris Gastrointestinal: anorexia, nausea  Genitourinary: 
decreased urination due to vasoconstriction of renal arteries. Also, difficulty 
urinating is not uncommon, as alpha-agonists such as ephedrine constrict the 
internal urethral sphincter, mimicking the effects of sympathetic nervous 
system stimulation. Nervous system: restlessness, confusion, insomnia, mild 
euphoria, mania/hallucinations (rare except in previously existing psychiatric 
conditions), delusions, formication (may be possible, but lacks documented 
evidence) paranoia, hostility, panic, agitation Respiratory : dyspnea, 
pulmonary edema Miscellaneous : dizziness, headache, tremor, 
hyperglycemic reactions, dry mouth The neurotoxicity of 1-Ephedrine is 
disputed.  
Contraindications 
Ephedrine should not be used in conjunction with certain 
antidepressants, namely SNRIs (serotonin-norepinephrine re-uptake 
inhibitors), as this increases the risk of the above symptoms due to excessive 
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serum levels of norepinephrine. Ephedrine should be used with caution in 
patients with inadequate fluid replacement, impaired adrenal 
function, hypoxia, hypercapnia, acidosis, hypertension, hyperthyroidism, pro
static hypertrophy,diabetes mellitus, cardiovascular disease, during delivery 
if maternal BP > 130/80 mmHg, and lactation.  
  Contraindications for the use of ephedrine include: closed angle 
glaucoma, phaeochromocytoma, asymmetric hypertrophy (idiopathic 
hypertrophic subaortic stenosis), concomitant or recent (previous 14 days) 
 monoamine oxidase inhibitor (MAOI) therapy, general anaesthesia with 
halogenated hydrocarbons (particularly halothane), tachyarrhythmias or 
ventricular fibrillation, hypersensitivity to ephedrine or other stimulants. 
Ephedrine should not be used at any time during pregnancy unless 
specifically indicated by a qualified physician and only when other options 
are unavailable.  
Recreational and illicit use 
Anecdotal reports have suggested that ephedrine helps studying, 
thinking, or concentrating to a greater extent than caffeine. Some students 
and some white-collar workers have used ephedrine (or Ephedra-containing 
herbal supplements) for this purpose, as well as some professional athletes 
and weightlifters.  
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Atropine 
  Atropine is a tropane alkaloid extracted from deadly nightshade 
(Atropabelladonna), jimsonweed (Daturastramonium), mandrake (Mandrag
ora officinarum) and other plants of the family Solanaceae 
Natural sources 
Atropine is found in many members of the Solanaceae family. The 
most commonly-found sources are Atropa belladonna, Datura inoxia, D 
metel, and D. stramonium. Other sources include members of 
the Brugmansia and Hyoscyamus genera. The Nicotiana genus (including the 
tobacco plant, N. tabacum) is also found in the Solanaceae family, but these 
plants do not contain atropine or other tropane alkaloids 
Synthesis 
Atropine can be synthesized by the reaction of tropine with tropic 
acid in the presence of hydrochloric acid. Chemistry and pharmacology 
Atropine is a racemic mixture of D-hyoscyamine and L-hyoscyamine, with 
most of its physiological effects due to L-hyoscyamine. Its pharmacological 
effects are due to binding to muscarinic acetylcholine receptors. It is an 
antimuscarinic agent. 
Physiological effects and uses 
Atropine increases firing of the sinoatrial node (SA) and conduction 
through the atrioventricular node (AV) of the heart, opposes the actions of  
 
 
36 
 
the vagus nerve, blocks acetylcholine receptor sites, and decreases bronchial 
secretions. In general, atropine lowers the parasympathetic activity of 
all muscles and glands regulated by the parasympathetic nervous system. 
This occurs because atropine is a competitive antagonist of the muscarinic 
acetylcholine receptors (acetylcholine being the main neurotransmitter used 
by the parasympathetic nervous system), therefore, it may cause swallowing 
difficulties and reduced secretions.  
Ophthalmic use 
Topical atropine is used as a cycloplegic, to temporarily paralyze 
the accommodation reflex, and as a mydriatic, to dilate the pupils. 
Resuscitation 
Injections of atropine are used in the treatment of bradycardia (an 
extremely low heart rate), asystole and pulseless electrical activity (PEA) 
in cardiac arrest. This works because the main action of the vagus nerve of 
the parasympathetic system on the heart is to decrease heart rate. Atropine 
blocks this action and, therefore, may speed up the heart rate. The usual 
dosage of atropine in bradyasystolic arrest is 0.5 to 1 mg IV push every three 
to five minutes, up to a maximum dose of 0.04 mg/kg. For symptomatic 
bradycardia, the usual dosage is 0.5 to 1.0 mg IV push, may repeat every 3 to 
5 minutes up to a maximum dose of 3.0 mg 
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Atropine is also useful in treating second-degree heart block Mobitz Type 1 
(Wenckebach block), and also third-degree heart block with a 
high Purkinje or AV-nodal escape rhythm.  in the heart, but atropine inhibits 
this action. 
Secretions and bronchoconstriction 
Atropine's actions on the parasympathetic nervous system inhibits 
salivary, sweat, and mucus glands. This can be useful in 
treating hyperhidrosis, and can prevent the death rattle of dying patients. 
 Treatment for organophosphate poisoning 
Atropine is not an actual antidote for organophosphate poisoning. 
However, by blocking the action of acetylcholine at muscarinic receptors, 
atropine also serves as a treatment for poisoning 
byorganophosphate insecticides and nerve gases, such as Tabun (GA), Sarin   
 (GB), Soman (GD) and VX.. 
Optical penalisation 
In refractive and accommodative amblyopia, when occlusion is not 
appropriate sometimes atropine is given to induce blur in the good eye. 
 Side-effects and overdose 
Adverse reactions to atropine include ventricular fibrillation, 
supraventricular or ventricular tachycardia, dizziness, nausea, blurred vision, 
loss of balance, dilated pupils, photophobia, dry mouth and potentially 
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extreme confusion,dissociative hallucinations and excitation especially 
amongst the elderly.  
Although atropine treats bradycardia (slow heart rate) in emergency 
settings, it can cause paradoxical heart rate slowing when given at very low 
doses, presumably as a result of central action in the CNS. Atropine is 
incapacitating at doses of 10 to 20 mg per person. Its LD50 is estimated to be 
453 mg per person (per oral) with a probit slope of 1.8. The antidote to 
atropine is physostigmine orpilocarpine.  
A common mnemonic used to describe the physiologic manifestations 
of atropine overdose is: "hot as a hare, blind as a bat, dry as a bone, red as a 
beet, and mad as a hatter". These associations reflect the specific changes of 
warm, dry skin from decreased sweating, blurry vision, decreased 
sweating/lacrimation, vasodilation, and central nervous system effects 
on muscarinic receptors, type 4 and 5. This set of symptoms is known 
as anticholinergic toxidrome, and may also be caused by other drugs with 
anticholinergic effects, such as diphenhydramine, phenothiazine 
antipsychotics and benztropine.  
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REVIEW OF LITERATURE 
1. Cardiovascular autonomic dysfunction and hemodynamic 
response to anesthetic induction in patients with coronary artery 
disease and diabetes mellitus 
 Cornelius keyl ,M.D, and et al 
Pre operative evaluation for cardiac autonomic neuropathy with 
spectral analysis of blood pressure and heart rate variability done for 60 
patients scheduled for coronary artery surgery , 30 suffering from diabetes . 
Heart rate and blood pressure before anesthetic induction and before and 
after tracheal intubation were compared between groups. There was no 
relationship between cardiovascular autonomic function and hemodynamic 
behavior during anesthetic induction. These findings indicate that increased 
hemodynamic instability during anesthetic induction is not obligatory in 
patients with diabete mellitus and autonomic dysfunction.  
2. Diabetic autonomic neuropathy : abnormal cardiovascular reaction 
under general anesthesia 
Knuttgen d.weidemann d, doehn m 
The influence of diabetic autonomic neuropathy upon the behavior of 
the circulatory system was investigated in 56 patients who had undergone 
ophthalmological surgery. During general anesthesia patients with diabetes 
experienced hypotensive reactions more often than non diabetes patients. 
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3. Diabetes-Induced Cardiac Autonomic Neuropathy 
Scott W. Harden 
  This review outlines the relationship between diabetes mellitus and  
autonomic neuropathy, with special emphasis on the neurophysiological 
pathology of  the cardiovascular system caused by this deadly epidemic. The 
high prevalence of diabetes combined with its association with cardiac 
autonomic neuropathy and the current lack of effective treatment options 
makes diabetic cardiac autonomic neuropathy a serious threat to a large 
portion of the human population.  
4. A non-invasive approach to cardiac autonomic neuropathy in 
patients with diabetes mellitus 
F. Weise, F. Heydenreich 
Ten insulin-dependent diabetic patients (29 ± 2 years) with a short to 
moderately long duration of diabetes (11 ± 1 years) and cardiac vagal 
neuropathy based on measurements of respiratory sinus arrhythmia were 
compared to 10 healthy volunteers (27 ± 1 years) before and after the 
administration of atropine and atropine plus propranolol. There was no 
significant difference between diabetics and controls after combined 
autonomic blockade. It was concluded that heart rate spectral power could 
serve as an indirect, non-invasive, quantitative and sensitive marker of early 
cardiac sympathetic damage. 
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5. Cardiac autonomic and peripheral neuropathy in newly diagnosed 
type 2 diabetic patients 
GR Kurashvili, RB Kurashvili, MG Khelashvili, LR Tsutskiridze, EL 
Shelestova & MN Kobaidze 
At diagnosis 20–30% of patients (pts) with type2 diabetes (T2DM) 
have neuropathy, that often goes unrecognized. 39 pts with newly diagnosed 
T2DM without known CV disease, ketoacidosis, alcoholism and/or chronic 
liver disease and non-diabetic nerve damages, not taking medications 
affecting CAN reflex tests. Ewing’s standard reflex tests were performed, 
severity of CAN was evaluated according to Jermendy, 1995. Standardized 
evaluation was conducted (Neurometer, Baltimore, MD), that discriminates 
between neuropathic and non-neuropathic pts and tests different nerve fiber 
types. CAN was observed in 53.85% of the patients; peripheral sensory 
dysfunction prevalence here was higher (35.9%), than in general population 
 
 
. 
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METHODOLOGY 
    A randomized controlled, prospective comparative study was done to 
compare the behavior of diabetic patient with cardiac autonomic neuropathy 
and non-diabetic patient without cardiac autonomic neuropathy during spinal 
anesthesia. The study was conducted after approval by the hospital ethical 
committee and an informed written consent was obtained from all. The 
sympathetic nervous system is stimulated in the early stages of diabetes and 
extended exposure of the adrenergic receptors to increased cathecalomines 
level together with hyperglycemic and insulin deficiency is believed to cause 
diabetic CAN. An imbalance of sympathetic and parasympathetic control of 
cardiac function can lead to silent myocardial ischemia, sudden cardiac death 
due to lethal arrhythmias, orthostatic hypotension, resting tachycardia, 
decreased baroreceptor sensitivity, exercise intolerance diastolic dysfunction 
and B.P invariability (sztajzel ,2004). There is a 2-3 fold increase in 
cardiovascular morbidity and mortality intra-operatively for patient with 
diabetes 
Noninvasive diagnostic methods assessing autonomic function allow 
identification of at risk patient pre-operatively and better prepare the 
anesthesiologist for potential hemodynamics.  This study aimed to evaluate 
the diabetic patient and control group pre-operatively for cardiac autonomic 
neuropathy with CANS – 504 (cardiac autonomic neuropathy system 
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analyzer). A total number of 50 ASA II & III patients belonging to age group 
of  40 –60 years  were divide into three groups 20 ,10, 20 respectively. 
Group I – patients with diabetic mellitus having cardiac autonomic 
neuropathy, group II –diabetic patient without cardiac autonomic neuropathy 
and group III –control patients non-diabetic without cardiac autonomic 
neuropathy. Those patients < 40 years and > 60 years & those of ASA IV 
were excluded from the study. Both male and females with diabetes mellitus 
more than 3 years are included in the case study. 
Along with routine investigations, pre operative evaluation for cardiac 
autonomic neuropathy is done with CANS 504 (cardiac autonomic 
neuropathy system analyzer). CANS 504 is an important tool to measure and 
diagnose autonomic dysfunction using ECG R-R interval and automatic B.P 
measurement.        
Understanding controls:   
1. 3 lead ECG  
2. B.P cuff  
3. valsalva probe  
4. spring loaded hand grip device 
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CANS – 504 
 
 
 
 
 
 
 
 
 
 
Operating instruction :  
  CANS 504 is connected to the PC through RS 232 serial 
communication. After connecting all accessories to the unit, patient should 
be in supine position. Attach ECG electrodes and record resting ECG,deep 
breathing ECG, supine ECG, valsalva ECG. B.P cuff attached to the patient 
.then record supine B.P, standing B.P, hand grip B.P (before hand grip and 
after 5 min.of 30 % hand grip). 
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Normal and abnormal values in autonomic study 
TEST normal borderline abnormal 
1.parasympathetic:  
 
 
 
 
 
    Valsalva 1.2 
 
1.1 – 1.2 
 
1.1 
 
    Deep breathing 
    [max:min hr] 15 BPM 
 
11 –14 BPM 
 
 
10 BPM 
 
   Standing 1.04 1.01 – 1.03 1.00 
2.Sympathetic 
   [b.p response] 
   standing(systolic) 
 
10 mmHg 
 
11- 29 
mmHg 
 
30mmHg 
 
   Exercise(diastolic)  16 mmHg 
 
11- 15 
mmHg 
 
10mmHg 
 
Under aseptic precaution, subarachanoid block given at L2 –L3 level, 
volume 3 ml of 0.5% bupivacine given. Sensory level obtained up to T4-T5 
level. Intra – operative recording of ECG rate and rhythm, B.P, pulse rate 
were done for each 5 minutes in first 30 minutes and then for each 15 
minutes till the end of surgery. Injection ephedrine 6mg given i.v if systolic 
B.P falls below 90mmHg or 20% of baseline values. Injection atropine 0.6 
mg given i.v pulse rate falls below 60/min. 
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Print out results of autonomic study using CANS 504 
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Print out results of autonomic study using CANS 504 
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STATISTICAL ANALYSIS: 
Variables were analyzed with ANOVA and POST HOC test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INJ. EPHEDRINE * Group Cross tabulation
      Group  
      1 2 3 Total
INJ. EPHEDRINE 
 
0 dose 
 
Count 4 2 12 18
% within Group 20.0% 20.0% 60.0% 36.0%
1 dose 
 
Count 3 4 8 15
% within Group 15.0% 40.0% 40.0% 30.0%
2 dose 
 
Count 5 4 0 9
% within Group 25.0% 40.0% .0% 18.0%
3 dose 
 
Count 6 0 0 6
% within Group 30.0% .0% .0% 12.0%
4 dose 
 
Count 2 0 0 2
% within Group 10.0% .0% .0% 4.0%
  
 
Total 
 
Count 20 10 20 50
% within Group 100.0% 100.0% 100.0% 100.0%
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INJ. ATROP * Group Cross tabulation   
      Group   
      1 2 3 Total
IN
J. 
A
T
R
O
P 
 
0 dose Count 3 5 19 27
% within Group 15.0% 50.0% 95.0% 54.0%
0dose Count 0 3 0 3
% within Group .0% 30.0% .0% 6.0%
1 dose Count 9 2 1 12
% within Group 45.0% 20.0% 5.0% 24.0%
2 dose Count 1 0 0 1
% within Group 5.0% .0% .0% 2.0%
nil Count 7 0 0 7
% within Group 35.0% .0% .0% 14.0%
  Total Count 20 10 20 50
% within Group 100.0% 100.0% 100.0% 100.0%
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Descriptives
   
  N Mean Std. Deviation Std. Error
0 MINUTES  
SYSTOLIC 
1 20 122.60 12.245 2.738 
2 10 125.60 10.617 3.357 
3 20 119.30 10.121 2.263
Total 50 121.88 11.150 1.577 
5 MINUTES 
SYSTOLIC 
1 20 120.90 11.021 2.464 
2 10 120.60 10.834 3.426 
3 20 115.60 8.647 1.934 
Total 50 118.72 10.212 1.444 
10 MINUTES 
SYSTOLIC 
1 20 112.70 11.952 2.673 
2 10 117.20 12.155 3.844 
3 20 113.30 7.349 1.643 
Total 50 113.84 10.316 1.459 
Total 5214.720 49  
 
ANOVA 
  F Sig. 
0 MINUTES  SYSTOLIC Between Groups 1.140 .328 
5 MINUTES SYSTOLIC Between Groups 1.597 .213 
10 MINUTES 
SYSTOLIC 
Between Groups 
.671 .516 
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ANOVA 
  F Sig. 
0 MINUTES 
DIASTOLIC 
Between Groups
2.474 .095 
5 MINUTES 
DIASTOLIC 
Between Groups
5.373 .008 
10 MINUTES 
DIASTOLIC 
Between Groups
.665 .519 
 
Descriptives 
   
  N Mean Std. Deviation Std. Error 
0 MINUTES 
DIASTOLIC 
1 20 78.80 7.523 1.682 
2 10 75.40 9.143 2.891 
3 20 73.70 6.062 1.355 
Total 50 76.08 7.548 1.067 
5 MINUTES 
DIASTOLIC 
1 20 78.50 6.354 1.421 
2 10 75.20 8.121 2.568 
3 20 72.30 4.118 .921 
Total 50 75.36 6.496 .919 
10 MINUTES 
DIASTOLIC 
1 20 73.50 9.528 2.131
2 10 71.80 8.351 2.641
3 20 70.70 4.824 1.079
Total 50 72.04 7.658 1.083
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Post Hoc Tests 
Multiple Comparisons
LSD 
Dependent Variable 
(I) Group 
(J) 
Group 
   
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
5 MINUTES 
DIASTOLIC 
1 
2 3.300 2.317 .161 
3 6.200* 1.892 .002 
2 
1 -3.300 2.317 .161 
3 2.900 2.317 .217 
3 
1 -6.200* 1.892 .002 
2 -2.900 2.317 .217 
 
Descriptives 
  N Mean Std. Deviation Std. Error 
15 MINUTES 
SYSTOLIC 
1 20 103.30 12.057 2.696 
2 10 107.00 10.467 3.310 
3 20 108.20 8.703 1.946 
Total 50 106.00 10.537 1.490 
15 MINUTES  
DIASTOLIC 
1 20 67.00 11.617 2.598 
2 10 69.20 9.004 2.847 
3 20 67.10 5.170 1.156 
Total 50 67.48 8.851 1.252 
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Descriptives 
   
  
N Mean 
Std. 
Deviation 
Std. 
Error 
20 MINUTES  
SYSTOLIC 
1 20 103.90 9.915 2.217 
2 10 100.00 9.707 3.070 
3 20 102.40 7.989 1.786 
Total 50 102.52 9.069 1.283 
20 MINUTES  
DIASTOLIC 
1 20 66.35 10.028 2.242 
2 10 60.20 9.543 3.018 
3 20 63.50 6.833 1.528 
Total 50 63.98 8.895 1.258 
 
 
 
ANOVA 
  F Sig. 
15 MINUTES 
SYSTOLIC 
Between 
Groups 
1.144 .327 
15 MINUTES  
DIASTOLIC 
Between 
Groups 
.229 .796 
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ANOVA 
  F Sig. 
20 MINUTES  
SYSTOLIC 
Between 
Groups 
.609 .548 
20 MINUTES  
DIASTOLIC 
Between 
Groups 
1.688 .196 
 
 
Descriptives 
  N Mean Std. Deviation Std. Error
25 MINUTES  
SYSTOLIC 
1 20 106.20 8.383 1.874 
2 10 102.60 8.746 2.766 
3 20 99.20 7.266 1.625 
Total 50 102.68 8.472 1.198 
25 MINUTES  
DIASTOLIC 
1 20 66.30 8.736 1.954 
2 10 63.60 6.586 2.083 
3 20 60.30 7.263 1.624 
Total 50 63.36 8.086 1.143 
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Post Hoc Tests 
 
Multiple Comparisons 
LSD 
Dependent Variable 
(I) 
Group
(J) 
Group
 
Mean 
Difference 
(I-J) Std. Error Sig. 
25 MINUTES  
SYSTOLIC 
1 2 3.600 3.108 .253
3 7.000* 2.538 .008
2 1 -3.600 3.108 .253
3 3.400 3.108 .280
3 1 -7.000* 2.538 .008
2 -3.400 3.108 .280
25 MINUTES  
DIASTOLIC 
1 2 2.700 3.012 .375
3 6.000* 2.459 .019
2 1 -2.700 3.012 .375
3 3.300 3.012 .279
3 1 -6.000* 2.459 .019
2 -3.300 3.012 .279
*. The mean difference is significant at the 0.05 level. 
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ANOVA 
  F Sig. 
30 MINUTES  
SYSTOLIC 
Between 
Groups 
.780 .464 
30 MINUTES  
DIASTOLIC 
Between 
Groups 
.397 .675 
 
Descriptives 
  
N Mean 
Std. 
Deviation Std. Error 
30 MINUTES  
SYSTOLIC 
1 20 104.90 8.296 1.855 
2 10 105.60 5.562 1.759 
3 20 102.40 7.989 1.786 
Total 50 104.04 7.682 1.086 
30 MINUTES  
DIASTOLIC 
1 20 66.00 7.894 1.765 
2 10 64.40 6.518 2.061 
3 20 64.20 5.540 1.239 
Total 50 64.96 6.679 .945 
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Descriptives 
 
 N Mean 
Std. 
Deviation 
Std. 
Error 
45 MINUTES  
SYSTOLIC 
1 20 101.20 8.345 1.866 
2 10 105.00 11.005 3.480 
3 20 108.30 5.777 1.292 
Total 50 104.80 8.514 1.204 
45 MINUTES  
DIASTOLIC 
1 20 63.10 9.301 2.080 
2 10 63.40 11.316 3.578 
3 20 69.20 3.518 .787 
Total 50 65.60 8.408 1.189 
 
ANOVA 
  F Sig. 
45 MINUTES  
SYSTOLIC 
Between 
Groups 
3.891 .027 
45 MINUTES  
DIASTOLIC 
Between 
Groups 
3.354 .044 
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Post Hoc Tests 
 
Multiple Comparisons 
LSD 
Dependent Variable 
(I) 
Group
(J) 
Group
 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
45 MINUTES  
SYSTOLIC 
1 
2 -3.800 3.119 .229 
3 -7.100* 2.546 .008 
2 
1 3.800 3.119 .229 
3 -3.300 3.119 .295 
3 
1 7.100* 2.546 .008 
2 3.300 3.119 .295 
45 MINUTES  
DIASTOLIC 
1 
2 -.300 3.110 .924 
3 -6.100* 2.540 .020 
2 
1 .300 3.110 .924 
3 -5.800 3.110 .068 
3 
1 6.100* 2.540 .020 
2 5.800 3.110 .068 
*. The mean difference is significant at the 0.05 level. 
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Descriptives 
   
 
 N Mean 
Std. 
Deviation 
Std. 
Error 
1 HOUR 
SYSTOLIC 
1 20 103.00 10.413 2.328 
2 10 108.60 5.502 1.740 
3 20 109.20 3.750 .839 
Total 50 106.60 7.869 1.113 
1 HOUR  
DIASTOLIC 
1 20 62.10 8.447 1.889 
2 10 65.20 5.827 1.843 
3 20 70.10 3.210 .718 
Total 50 65.92 7.148 1.011 
 
ANOVA 
  F Sig. 
1 HOUR 
SYSTOLIC 
Between 
Groups 
3.927 .026 
1 HOUR  
DIASTOLIC 
Between 
Groups 
8.180 .001 
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Post hoc  test  :   Multiple Comparisons 
LSD 
Dependent 
Variable 
(I) 
Group
(J) 
Group
 
Mean 
Difference (I-J) Std. Error Sig. 
1 HOUR 
SYSTOLIC 
1 
2 -5.600 2.880 .058 
3 -6.200* 2.352 .011 
2 
1 5.600 2.880 .058 
3 -.600 2.880 .836 
3 
1 6.200* 2.352 .011 
2 .600 2.880 .836 
1 HOUR  
DIASTOLIC 
1 
2 -3.100 2.435 .209 
3 -8.000* 1.988 .000 
2 
1 3.100 2.435 .209 
3 -4.900* 2.435 .050 
3 
1 8.000* 1.988 .000 
2 4.900* 2.435 .050 
*. The mean difference is significant at the 0.05 level. 
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Descriptives 
   
  
N Mean 
Std. 
Deviation 
Std. 
Error 
1.15 HOUR 
SYSTOLIC 
1 20 103.50 10.971 2.453 
2 10 106.40 10.575 3.344 
3 20 111.10 5.562 1.244 
Total 50 107.12 9.546 1.350 
1.15 HOUR  
DIASTOLIC 
1 20 64.40 10.455 2.338 
2 10 64.20 8.456 2.674 
3 20 71.30 3.389 .758 
Total 50 67.12 8.477 1.199 
ANOVA 
  F Sig. 
1.15 HOUR 
SYSTOLIC 
Between 
Groups 
3.537 .037 
1.15 HOUR  
DIASTOLIC 
Between 
Groups 
4.660 .014 
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Post Hoc Tests 
Multiple Comparisons 
LSD 
Dependent Variable 
(I) 
Group
(J) 
Group
 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
1.15 HOUR 
SYSTOLIC 
1 
2 -2.900 3.519 .414 
3 -7.600* 2.874 .011 
2 
1 2.900 3.519 .414 
3 -4.700 3.519 .188 
3 
1 7.600* 2.874 .011 
2 4.700 3.519 .188 
1.15 HOUR  
DIASTOLIC 
1 
2 .200 3.062 .948 
3 -6.900* 2.500 .008 
2 
1 -.200 3.062 .948 
3 -7.100* 3.062 .025 
3 
1 6.900* 2.500 .008 
2 7.100* 3.062 .025 
*. The mean difference is significant at the 0.05 level. 
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Descriptives 
   
  
N Mean 
Std. 
Deviation 
Std. 
Error 
1.30 HOUR 
SYSTOLIC 
1 20 107.80 7.281 1.628 
2 10 112.00 5.657 1.789 
3 20 111.40 5.315 1.189 
Total 50 110.08 6.401 .905 
1.30 HOUR  
DIASTOLIC 
1 20 69.50 9.035 2.020 
2 10 69.00 6.683 2.113 
3 20 71.70 2.993 .669 
Total 50 70.28 6.689 .946 
 
 
ANOVA 
  F Sig. 
1.30 HOUR 
SYSTOLIC 
Between 
Groups 2.254 .116 
1.30 HOUR  
DIASTOLIC 
Between 
Groups .762 .472 
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Descriptives 
   
  N Mean Std. Deviation 
Std. 
Error 
1.45 HOUR  
SYSTOLIC 
1 20 108.90 6.274 1.403 
2 10 115.00 5.354 1.693 
3 20 112.40 5.134 1.148 
Total 50 111.52 6.028 .852 
1.45 HOUR  
DIASTOLIC 
1 20 69.40 6.524 1.459 
2 10 71.20 7.254 2.294 
3 20 71.50 2.743 .613 
Total 50 70.60 5.485 .776 
 
 
ANOVA 
  F Sig. 
1.45 HOUR  
SYSTOLIC 
Between 
Groups 
4.272 .020
1.45 HOUR  
DIASTOLIC 
Between 
Groups 
.801 .455
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Post Hoc Tests 
 
 
Multiple Comparisons 
LSD 
Dependent Variable 
(I) 
Group
(J) 
Group
 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
1.45 HOUR  
SYSTOLIC 
1 
2 -6.100* 2.193 .008 
3 -3.500 1.790 .057 
2 
1 6.100* 2.193 .008 
3 2.600 2.193 .242 
3 
1 3.500 1.790 .057 
2 -2.600 2.193 .242 
1.45 HOUR  
DIASTOLIC 
1 
2 -1.800 2.133 .403 
3 -2.100 1.741 .234 
2 
1 1.800 2.133 .403 
3 -.300 2.133 .889 
3 
1 2.100 1.741 .234 
2 .300 2.133 .889 
*. The mean difference is significant at the 0.05 level. 
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Descriptives 
   
  
N Mean 
Std. 
Deviation 
Std. 
Error 
2 HOUR 
SYSTOLIC 
1 20 110.80 5.248 1.173 
2 10 115.80 4.566 1.444 
3 20 112.50 5.021 1.123 
Total 50 112.48 5.261 .744 
2 HOUR  
DIASTOLIC 
1 20 72.70 6.465 1.446 
2 10 73.40 5.816 1.839 
3 20 70.80 2.783 .622 
Total 50 72.08 5.158 .729 
 
ANOVA 
  F Sig. 
2 HOUR 
SYSTOLIC 
Between 
Groups 
3.292 .046
2 HOUR  
DIASTOLIC 
Between 
Groups 
1.092 .344
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Post Hoc Test 
 
Multiple Comparisons 
LSD 
Dependent 
Variable 
(I) 
Group
(J) 
Group
 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
2 HOUR 
SYSTOLIC 
1 2 -5.000* 1.949 .014 
3 -1.700 1.591 .291 
2 1 5.000* 1.949 .014 
3 3.300 1.949 .097 
3 1 1.700 1.591 .291 
2 -3.300 1.949 .097 
2 HOUR  
DIASTOLIC 
1 2 -.700 1.994 .727 
3 1.900 1.628 .249 
2 1 .700 1.994 .727 
3 2.600 1.994 .199 
3 1 -1.900 1.628 .249 
2 -2.600 1.994 .199 
*. The mean difference is significant at the 0.05 level. 
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Descriptives 
   
  
N Mean 
Std. 
Deviation 
Std. 
Error 
0 MINUTES  PULSE 
RATE 
1 20 82.90 10.254 2.293
2 10 80.60 7.183 2.272
3 20 77.60 6.443 1.441
Total 50 80.32 8.491 1.201
5 MINUTES PULSE  
RATE 
1 20 81.20 8.269 1.849
2 10 77.00 7.257 2.295
3 20 78.00 5.912 1.322
Total 50 79.08 7.275 1.029
 
 
ANOVA 
  F Sig. 
0 MINUTES  PULSE 
RATE 
Between 
Groups 
2.038 .142
5 MINUTES PULSE  
RATE 
Between 
Groups 
1.509 .232
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Descriptives 
   
  
N Mean 
Std. 
Deviation 
Std. 
Error 
10 MINUTES  
PULSE RATE 
1 20 80.90 9.279 2.075 
2 10 77.00 5.907 1.868 
3 20 78.45 6.901 1.543 
Total 50 79.14 7.788 1.101 
15 MINUTES  
PULSE RATE 
1 20 78.15 8.431 1.885 
2 10 77.70 4.322 1.367 
3 20 77.75 7.636 1.707 
Total 50 77.90 7.324 1.036 
 
 
ANOVA 
  F Sig. 
10 MINUTES  
PULSE RATE 
Between 
Groups 
.965 .388
15 MINUTES  
PULSE RATE 
Between 
Groups 
.019 .981
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Post Hoc Tests 
 
 
Multiple Comparisons 
LSD 
Dependent Variable 
(I) 
Group
(J) 
Group
 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
10 MINUTES  
PULSE RATE 
1 
2 3.900 3.018 .203 
3 2.450 2.465 .325 
2 
1 -3.900 3.018 .203 
3 -1.450 3.018 .633 
3 
1 -2.450 2.465 .325 
2 1.450 3.018 .633 
15 MINUTES  
PULSE RATE 
1 
2 .450 2.895 .877 
3 .400 2.364 .866 
2 
1 -.450 2.895 .877 
3 -.050 2.895 .986 
3 
1 -.400 2.364 .866 
2 .050 2.895 .986 
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Descriptives 
   
  
N Mean 
Std. 
Deviation 
Std. 
Error 
20 MINUTES  
PULSE RATE 
1 20 76.50 10.425 2.331 
2 10 75.40 5.582 1.765 
3 20 77.30 6.027 1.348 
Total 50 76.60 7.902 1.118 
25 MINUTES  
PULSE RATE 
1 20 78.40 12.133 2.713 
2 10 75.90 3.957 1.251 
3 20 77.30 5.805 1.298 
Total 50 77.46 8.596 1.216 
 
 
ANOVA 
  F Sig. 
20 MINUTES  
PULSE RATE 
Between 
Groups .189 .829 
25 MINUTES  
PULSE RATE 
Between 
Groups .279 .758 
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Descriptives 
   
  
N Mean 
Std. 
Deviation 
Std. 
Error 
30  MINUTES  
PULSE  RATE 
1 20 77.40 12.696 2.839 
2 10 71.90 5.174 1.636 
3 20 76.55 7.141 1.597 
Total 50 75.96 9.568 1.353 
45 MINUTES  
PULSE  RATE 
1 20 78.30 13.223 2.957 
2 10 70.40 10.824 3.423 
3 20 78.55 6.716 1.502 
Total 50 76.82 10.832 1.532 
 
ANOVA 
  Sum of Squares df 
Mean 
Square 
30  MINUTES  
PULSE  RATE 
Between 
Groups 213.270 2 106.635 
Within Groups 4272.650 47 90.907 
Total 4485.920 49  
45 MINUTES  
PULSE  RATE 
Between 
Groups 515.830 2 257.915 
Within Groups 5233.550 47 111.352 
Total 5749.380 49  
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ANOVA 
  F Sig. 
30  MINUTES  
PULSE  RATE 
Between 
Groups 1.173 .318 
45 MINUTES  
PULSE  RATE 
Between 
Groups 2.316 .110 
 
   
  
N Mean 
Std. 
Deviation 
Std. 
Error 
1.15 HOUR PULSE  
RATE 
1 20 82.90 11.116 2.486 
2 10 78.10 5.971 1.888 
3 20 77.05 4.893 1.094 
Total 50 79.60 8.444 1.194 
1.30 HOUR  PULSE 
RATE 
1 20 81.90 10.021 2.241 
2 10 76.60 6.802 2.151 
3 20 77.20 6.271 1.402 
Total 50 78.96 8.283 1.171 
 
ANOVA 
  F Sig. 
1.15 HOUR PULSE  
RATE 
Between 
Groups 2.786 .072 
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ANOVA 
  F Sig. 
1.15 HOUR PULSE  
RATE 
Between 
Groups 2.786 .072 
1.30 HOUR  PULSE 
RATE 
Between 
Groups 
2.223 .120 
 
Descriptives 
1  HOUR  PULSE RATE 
   
 
N Mean 
Std. 
Deviation 
Std. 
Error   
1 20 81.90 13.970 3.124  
2 10 80.30 8.845 2.797  
3 20 77.90 5.046 1.128  
Total 50 79.98 10.159 1.437  
 
ANOVA 
1  HOUR  PULSE RATE 
 Sum of 
Squares df 
Mean 
Square F Sig. 
Between 
Groups 161.280 2 80.640 .774 .467 
Within Groups 4895.700 47 104.164   
Total 5056.980 49    
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Descriptives 
   
  N Mean Std. Deviation 
Std. 
Error 
1.45 HOUR PULSE 
RATE 
1 20 80.75 8.711 1.948 
2 10 77.20 3.795 1.200 
3 20 77.30 6.062 1.355 
Total 50 78.66 7.021 .993 
2 HOUR  PULSE 
RATE 
1 20 82.60 7.870 1.760 
2 10 76.60 5.254 1.661 
3 20 77.40 5.623 1.257 
Total 50 79.32 6.982 .987 
 
 
 
ANOVA 
  F Sig. 
1.45 HOUR PULSE 
RATE 
Between 
Groups 
1.508 .232
2 HOUR  PULSE 
RATE 
Between 
Groups 
4.209 .021
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Post Hoc Tests 
Multiple Comparisons 
LSD 
Dependent Variable (I) Group
(J) 
Group
 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
2 HOUR  PULSE 
RATE 
1 
2 6.000* 2.543 .023 
3 5.200* 2.076 .016 
2 
1 -6.000* 2.543 .023 
3 -.800 2.543 .754 
3 
1 -5.200* 2.076 .016 
2 .800 2.543 .754 
*. The mean difference is significant at the 0.05 level. 
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RESULTS 
             In group I, during spinal anesthesia, the fall in B.P was more 
frequent (75%) and they need more doses of inj. Ephedrine (42%) and   33 % 
patient in group I are non reactive to inj. Ephedrine and they need inotropic 
support for B.P stability. 5 patients in group I have abnormal results i.e grade 
II  in all five test of autonomic function study .Those five patients were non 
responsive to inj. ephedrine during hypotensive reactions .They need 
inotropic support for hemodynamic stability . The occurrence of bradycardia 
(50%) during hypotensive reaction is also frequent and need 
atropine(40%).In group II ,fall in B.P was frequent(40%)but less than group 
I and more frequent than group III. In group III fall in B.P was less frequent 
(18%) and need less doses of inj. Ephedrine (15%).Fall in B.P can be 
managed even with i.v fluids in most cases .hypotensive reactions are less 
frequently accompanied with bradycardia(10%).From the ANOVA and 
POST HOC tset we can find a significant difference in systolic and diastolic 
B.P between group I and GROUP III. But there was less significant 
difference in B.P between group I and groupII ,group II and group III. From 
ANOVA we find significant difference in pulse rate between group I , II , III 
at various time interval during intra – operatively. 
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DISCUSSION 
                  Results of this study indicate that fall in B.P and bradycardia are 
more frequent in group I than group II and group III. This indicates that 
diabetic patients with cardiac neuropathy are more liable for hemodynamic 
variability than diabetes patients without cardiac neuropathy and non 
diabetic without cardiac neuropathy. Diabetes patients with abnormal (grade 
2 ) in all five autonomic dysfunction need inotropic support for B.P stability. 
Perhaps the most important things we can do for our patients with diabetes 
are to make them aware of autonomic neuropathy ,to let them know whether 
they have it and to help them keep blood sugar level in an acceptable range 
and explain the risk during regional anesthesia. Doing so not only help to 
reduce the risk of intra-operative morbidity and mortality but also lower the 
risk of heart disease ,diabetic eye ,kidney and nerve disease ,each of which 
patient dearly want to avoid. With a brief 15 minutes autonomic study we 
can anticipate the risk during anesthesia and can help patients live longer, 
healthier lives. 
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CONCLUSION 
 
1. We found a significant correlation between degree of autonomic 
dysfunction and largest drop in B.P variability in heart rate and rhythm 
2. These results prove atypical hemodynamic behavior and extreme B.P 
instability in diabetes patients with cardiac autonomic neuropathy 
3. Therefore we consider it to be very helpful to check the cardiovascular 
reflectory status of diabetes patient pre-operatively ,so that we can 
anticipate the risk during anesthesia in such patients  
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PROFORMA 
 
Group      :         1                         2                       3 
Name    : 
Age    :   Sex  :    
I.P.  No.   : 
Unit    : 
Diagnosis   : 
Surgical  procedure       : 
 
Pre- operative  Examination  :  
                    Routine  H/O     
                    Height  
        Weight 
        Pulse rate 
                    B.P 
                    R.R. 
                    C.V.S. 
                    R.S 
Investigations: 
                      Hb% 
         Blood sugar 
         Serum Urea 
          Serum Creatinine 
                      B.T 
                     C.T. 
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  ASA – PS  Grade :     
                  Procedure: 
   
  
 
Intravenous  fluid  replacement : 
 
Blood  no. of  units  used : 
 
Post-operative  vitals: 
 
 
 
 
 
 
 
                                   B.P  
Pulse 
Rate/rhythm 
 
ECG  
Rate/rhythm 
 systolic diastolic mean 
 
Every 5 
mins for 30 
mins 
     
Every 15 
mins till the 
end of the 
surgery 
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Group 1 diabetic with peripheral neuropathy 
Sl.No  0 min sys 0 min dia   5 min sys  5 min dias 10 minsys 10 min dia 15 min sys 15 min dias20 min sy   20 min dia 25 min sys 25 min dia 30 min sys 30 min dia 
1 130 70 130 70 100 60 90 56 110 64 108 64 108 64 
2 110 80 110 80 90 54 120 80 110 70 112 74 112 76 
3 120 80 120 84 120 86 116 84 114 80 110 74 120 76 
4 112 66 108 66 108 66 94 56 88 52 100 62 100 60 
5 126 84 124 80 130 84 124 86 110 84 114 84 112 76 
6 128 84 124 84 116 82 110 82 110 82 118 84 108 82 
7 118 86 114 82 110 82 94 58 100 58 96 54 98 56 
8 114 74 116 76 116 74 106 64 104 69 108 66 108 70 
9 136 84 134 84 124 80 100 72 92 56 100 64 94 60 
10 100 72 100 70 94 64 92 64 110 78 102 68 100 64 
11 110 68 110 70 108 69 100 56 92 62 90 60 88 54 
12 128 86 124 84 126 86 120 76 106 72 100 64 88 54 
13 110 74 108 74 110 73 90 58 120 74 116 70 110 72 
14 122 76 128 82 120 76 114 74 114 70 120 74 114 74 
15 140 86 138 86 134 84 100 64 90 52 108 68 104 62 
16 110 68 110 70 104 68 104 70 106 68 110 64 104 64 
17 130 84 126 78 108 70 92 60 84 52 106 64 104 66 
18 124 76 124 80 100 60 90 52 108 64 110 56 106 64 
19 148 92 140 86 110 72 90 48 110 60 106 62 110 64 
20 136 86 130 84 126 80 120 80 100 60 90 50 110 62 
sGroup 1 diabetic with peripheral neuropathy 
Sl.no 45 m sys 45 min dia 1 h sys 1 h dia 1.15 sys 1.15 dia 1.30 sys 1.30 dia 1.45 sys 1.45 dia 2 h sys 2 h dia 0 min p.r 5 min p.r 
1 94 56 114 70 110 70 110 70 120 74 120 74 86 90 
2 100 68 92 54 110 68 116 74 124 72 124 84 98 92 
3 100 60 94 50 124 84 114 78 116 76 118 82 74 76 
4 100 62 104 64 106 64 110 68 108 66 104 66 86 84 
5 114 76 118 76 118 90 110 82 114 80 110 76 94 96 
6 92 52 106 64 116 74 118 76 108 72 112 84 92 86 
7 106 68 104 56 96 64 108 64 104 64 108 74 84 76 
8 110 64 110 70 110 74 108 74 110 78 114 74 68 72 
9 90 56 110 64 92 60 102 64 102 64 108 62 98 84 
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10 96 60 94 62 88 54 108 82 106 76 106 72 68 68 
11 106 62 96 62 92 58 106 82 104 64 106 64 74 70 
12 108 82 92 60 90 56 94 56 104 66 110 70 68 72 
13 112 80 108 74 96 62 88 52 106 68 106 70 89 84 
14 120 74 122 74 110 68 110 74 110 76 112 74 90 92 
15 92 54 110 62 92 54 106 60 108 64 108 62 92 90 
16 100 68 110 64 110 68 108 74 110 74 106 72 86 84 
17 96 60 90 54 104 60 106 62 108 62 108 70 76 78 
18 92 50 110 66 88 48 106 56 96 54 116 74 68 74 
19 100 56 88 50 114 56 120 72 112 70 110 80 88 82 
20 96 54 88 46 104 56 108 70 108 68 110 70 79 74 
Group 1 diabetic with peripheral neuropathy 
Sl.No 10 min p.r 15 min p.r 20 min p.r 25 min p.r 30 min p.r 45 min p.r 1 h p.r 1.15 pr 1.30 p.r 1.45 p.r 2 h p.r Sex inj ephedrine inj atrophine 
1 94 84 90 84 90 84 96 92 98 90 92 Male  2 dose nil 
2 96 84 84 80 82 80 88 86 84 90 94 female  2 dose nil 
3 74 78 84 74 72 74 78 76 90 84 84 female  1 dose  nil 
4 84 88 88 84 84 80 84 86 90 84 84 Male  1 dose  nil 
5 92 84 86 88 84 98 94 96 92 93 92 female  0 dose nil 
6 84 84 86 84 85 82 84 84 90 86 86 Male  1 dose  nil 
7 74 76 76 72 68 56 92 86 88 88 82 female  3 dose 1 dose 
8 74 78 74 72 74 74 76 72 72 74 74 female  o dose  nil 
9 84 72 74 66 60 54 98 96 90 88 78 Male  3 dose 1 dose 
10 70 71 64 58 86 92 78 74 72 74 74 Male  3 dose 1 dose 
11 70 68 64 62 56 100 86 82 80 80 78 female  2 dose 1 dose 
12 78 72 70 64 56 62 102 74 62 58 98 Male  4 dose  2 dose 
13 86 75 74 64 56 98 100 64 66 76 74 female  2 dose 1 dose 
14 92 88 80 82 82 82 80 84 88 84 84 Male  0 dose o dose 
15 90 92 88 90 88 74 72 70 70 74 74 female  3 dose o dose 
16 88 80 82 86 88 90 86 92 90 88 90 female  o dose  o dose 
17 68 64 56 98 96 68 72 74 78 80 80 Male  3 dose 1 dose 
18 72 65 55 104 89 74 66 68 74 66 68 Male  4 dose  1 dose 
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19 80 90 81 80 84 78 52 100 76 78 84 female  3 dose 1 dose 
20 68 70 74 76 68 66 54 102 88 80 82 Male  2 dose 1 dose 
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Group 2 diabetic without peripheral neuropathy 
Sl.No  0 min sys 0 min dia   5 min sys  5 min dias 10 minsys 10 min dia 15 min sys 15 min dias20 min sy   20 min dia 25 min sys 25 min dia 30 min sys 30 min dia 
1 126 78 124 76 120 70 110 68 108 66 100 56 96 56 
2 138 88 130 86 130 80 128 72 100 62 88 52 110 74 
3 126 76 118 78 110 80 100 76 92 56 110 76 108 58 
4 142 84 138 84 138 78 110 78 94 52 110 68 104 56 
5 108 72 104 70 100 64 100 68 110 70 108 68 104 68 
6 134 86 130 84 124 80 100 76 90 48 110 64 110 70 
7 122 74 120 70 118 70 110 62 92 48 110 62 108 64 
8 118 70 110 70 112 72 102 68 90 56 88 62 110 68 
9 128 68 124 74 120 70 118 76 116 74 100 64 110 70 
10 114 58 108 60 100 54 92 48 108 70 102 64 96 60 
Group 2 diabetic without peripheral neuropathy 
Sl.no 45 m sys 45 min dia 1 h sys 1 h dia 1.15 sys 1.15 dia 1.30 sys 1.30 dia 1.45 sys 1.45 dia 2 h sys 2 h dia 0 min p.r 5 min p.r 
1 92 54 110 54 112 66 116 56 120 72 118 70 76 78 
2 108 52 110 58 94 52 112 72 120 78 118 72 80 82 
3 110 64 112 68 112 70 120 72 120 72 118 80 92 88 
4 92 56 112 64 110 70 118 72 116 70 118 72 86 86 
5 110 64 104 68 98 60 106 64 108 64 108 66 74 72 
6 120 86 118 74 120 68 118 74 122 80 120 86 76 78 
7 112 70 110 70 116 74 110 76 114 78 110 76 70 68 
8 108 70 98 64 86 48 104 60 108 56 120 70 78 70 
9 112 70 108 68 110 70 108 74 112 74 118 70 84 80 
10 86 48 104 64 106 64 108 70 110 68 110 72 90 68 
Group 2 diabetic without peripheral neuropathy 
Sl.No 10 min p.r 15 min p.r 20 min p.r 25 min p.r 30 min p.r 45 min p.r 1 h p.r 1.15 pr 1.30 p.r 1.45 p.r 2 h p.r inj ephedrine i nj atrophine Sex 
1 76 74 70 72 74 78 80 72 70 76 78 1 dose 0dose female  
2 86 84 80 76 72 70 76 78 72 76 78 2 dose o dose male  
3 82 80 88 82 80 86 88 82 88 80 82 1 dose o dose male  
4 84 86 76 78 62 54 98 90 88 80 80 2 dose  1 dose female  
5 70 74 70 77 70 72 70 72 72 72 70 0 dose 0dose male  
6 76 75 70 74 70 76 74 76 74 72 70 1 dose  o dose  male  
7 68 78 74 76 72 70 70 72 70 74 70 1 dose 0 dose female  
8 74 74 74 68 67 72 79 75 74 78 74 2 dose  0dose male  
9 80 76 78 76 78 76 80 84 80 82 80 0 dose  0dose male  
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10 74 76 74 80 74 50 88 80 78 82 84 2 dose  1 dose male  
 
 
Group 3 non diabetic without peripheral neuropathy 
Sl.No  
0 min sys 0 min 
dia   
5 min 
sys  
5 min 
dias 
10 
minsys 
10 min 
dia 
15 min 
sys 
15 min dias20 min 
sy   
20 min 
dia 
25 min 
sys 
25 min 
dia 
30 min 
sys 
30 min 
dia 
1 134 82 130 78 124 74 118 74 118 74 108 70 110 72 
2 122 78 118 76 108 80 106 74 100 70 104 72 98 64 
3 114 72 112 72 112 68 108 68 108 70 98 60 90 56 
4 108 64 106 68 106 76 110 74 102 64 94 58 88 54 
5 110 70 110 70 112 72 110 68 104 64 100 60 102 64 
6 124 84 118 80 120 78 116 68 110 64 102 66 96 58 
7 110 68 108 70 102 64 92 60 88 56 110 58 108 64 
8 144 86 138 80 130 74 110 64 98 58 90 54 120 68 
9 132 80 128 80 124 74 128 76 108 74 102 60 98 64 
10 106 72 104 70 106 72 108 70 98 64 102 60 104 64 
11 112 68 108 70 104 68 100 64 94 60 100 64 102 64 
12 120 74 118 72 118 76 120 68 110 64 100 60 104 68 
13 130 74 116 70 110 70 100 68 94 56 88 50 110 70 
14 110 68 108 70 110 64 100 60 98 54 100 58 104 64 
15 126 70 120 68 118 64 108 60 104 56 96 54 88 52 
16 114 70 112 72 110 70 100 62 94 52 86 46 104 64 
17 122 72 120 70 118 70 118 64 116 68 112 68 110 70 
18 110 74 110 70 110 68 100 70 98 70 98 68 104 70 
19 120 80 112 72 110 64 102 60 96 60 88 50 108 70 
20 118 68 116 68 114 68 110 70 110 72 106 70 100 64 
 
